Frankfurt
07.08.26 | 15:25
4,080 Euro
+3,03 % +0,120
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | INVENTIVA: Inventiva Announces Preliminary Financial Results for the First Half of 2026 | 892 | GlobeNewswire (Europe) | Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026
Daix (France), New York City (New York, United States), July 30, 2026 - Inventiva (Euronext... ► Artikel lesen | |
| 29.07. | Inventiva S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.07. | Cantor Fitzgerald initiates Inventiva stock with overweight rating | 16 | Investing.com | ||
| 09.07. | INVENTIVA: Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants | 1.159 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), July 9, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 06.07. | Inventiva S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 02.07. | INVENTIVA: Results of the Votes of the Combined Shareholders' General Meeting of June 30, 2026 | 549 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), July 2, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 30.06. | Inventiva S.A. (IVA) is One of the Best Stocks Under $10 Offering More Than 50% Upside | 12 | Insider Monkey | ||
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 12.06. | INVENTIVA: Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing | 650 | GlobeNewswire (Europe) | Repaid in full the existing EIB Loans1 in an amount of approximately €62 million and completed repurchase of all 2,266,023 existing EIB Tranche A Warrants and 700,000 of existing EIB Tranche B Warrants2... ► Artikel lesen | |
| 12.06. | Inventiva S.A. - 6-K, Report of foreign issuer | 12 | SEC Filings | ||
| 09.06. | INVENTIVA: Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents | 785 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), June 9,2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 09.06. | INVENTIVA: Statement of Total Voting Rights and Shares Forming The Company's Share Capital as of May 22, 2026 | 394 | GlobeNewswire (Europe) | Article R. 22-10-23 of the French Commercial Code
Market: Euronext Paris
ISIN code / Mnemo: FR0013233012 / IVA
Web site: www.inventivapharma.com
DateNumber of Shares OutstandingTotal... ► Artikel lesen | |
| 03.06. | Inventiva S.A. - 6-K, Report of foreign issuer | 12 | SEC Filings | ||
| 02.06. | INVENTIVA: Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout | 835 | GlobeNewswire (Europe) | Secured a new debt financing with funds and accounts managed by BlackRock and Claret Capital Partners, respectively for up to €130 million in committed tranches, subject to conditions, plus an additional... ► Artikel lesen | |
| 02.06. | INVENTIVA: Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris | 388 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), June 2, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 02.06. | INVENTIVA: Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris | 843 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), June 2, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 27.05. | Inventiva S.A reports Q1 results | 2 | Seeking Alpha | ||
| 26.05. | INVENTIVA: Inventiva Reports 2026 First Quarter Financial Information | 892 | GlobeNewswire (Europe) | Cash and cash equivalents at €75.0 million, and €121.5 million in short-term deposits2
Daix (France), New York City (New York, United States), May 26, 2026 - Inventiva (Euronext Paris and NASDAQ:... ► Artikel lesen | |
| 22.05. | Inventiva S.A. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 21.05. | INVENTIVA: Inventiva to Present at 2026 Jefferies Global Healthcare Conference | 428 | GlobeNewswire (Europe) | Daix (France), New York (United States), May 21, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 13.05. | INVENTIVA: Inventiva to Present Abstracts at the EASL Congress 2026 | 474 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), May 13, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 12,100 | 0,00 % | EyePoint, Inc. - 10-Q, Quarterly Report | ||
| EDWARDS LIFESCIENCES | 77,40 | -0,26 % | Edwards Lifesciences Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| HAPPY BELLY FOOD GROUP | 0,950 | -2,06 % | Happy Belly Food Group Inc.: Happy Belly Food Group Promotes Ian Thomas to Chief Financial Officer as Franchising Growth Continues to Accelerate | Toronto, Ontario--(Newsfile Corp. - August 6, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 223,00 | +0,50 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results | View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/jazz-pharmaceuticals-announces-second-quarter-2026-financial-results-302841455.html
► Artikel lesen | |
| DAIICHI SANKYO | 14,894 | -0,98 % | Daiichi Life Group Earnings Up In Q1; Maintains FY27 Outlook | TOKYO (dpa-AFX) - Daiichi Life Group, Inc. (8750.T, DLICY), a Japanese insurance holding company, on Friday reported higher net income in the first quarter compared with the previous year. For... ► Artikel lesen | |
| AYTU BIOPHARMA | 1,900 | -100,00 % | Aytu BioPharma, Inc.: Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 | DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 33,390 | -3,86 % | Rigel Pharmaceuticals, Inc.: Rigel Reports Second Quarter 2026 Financial Results | Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 3,035 | -1,94 % | NRx Pharmaceuticals, Inc.: FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval | FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters.Remaining item relates to manufacturer certification... ► Artikel lesen | |
| TUHURA BIOSCIENCES | 1,820 | 0,00 % | TuHURA Biosciences, Inc.: TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers | The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination... ► Artikel lesen | |
| CGN MINING | 0,314 | +2,61 % | CGN MINING (01164): OPERATIONAL STATEMENT FOR THE SECOND QUARTER OF 2026 | ||
| CHINA SHINEWAY PHARMACEUTICAL GROUP | 0,870 | +1,75 % | SHINEWAY PHARM (02877): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 MAY 2026 | ||
| FUTURA MEDICAL | 0,006 | 0,00 % | Futura Medical erhält EU-Zulassung für Eroxon Intense Gel | ||
| BAYER | 49,810 | +0,83 % | DAX vor spannender Woche - und Rekorden? Bayer, Siemens Energy, Commerzbank und Allianz mit ... | Ungeachtet der geopolitischen Krisenherde könnte die überwiegend positiv aufgenommene Berichtssaison der DAX-Konzern auch in der neuen Woche Rückenwind verleihen. Sinkende Ölpreise und starke Quartalszahlen... ► Artikel lesen | |
| MERCK KGAA | 143,65 | -1,03 % | Neue Folge "Börse, Baby!": Earnings-Alarm: Jetzt entscheidet sich der KI-Boom | Die KI-Euphorie bekommt erste Risse: Trotz starker Quartalszahlen geraten Tech-Aktien kräftig unter Druck. Ist das noch eine gesunde Korrektur? Die Berichtssaison zeigt derzeit, wie hoch die Erwartungen... ► Artikel lesen | |
| NOVO NORDISK | 40,970 | -0,06 % | Novo Nordisk, Johnson & Johnson und Co. setzen auf Plattformen - warum einzelne Medikamente für Big Pharma längst nicht mehr ausreichen |
INVENTIVA SA ADR gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +3,03 % bei einem Aktienkurs von 4,080 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.